Roche's Tecentriq Disappoints In Ovarian Cancer Study
Another Setback For Checkpoint Inhibitors In Challenging Disease
Executive Summary
PD-1/PDL-1 inhibitors have not proved effective for ovarian cancer on their own or in combinations. Now Roche's Tecentriq, combined with the firm's blockbuster Avastin, has suffered a similar fate to Merck KGaA and Pfizer's Bavencio in failing to improve survival.